12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aubagio teriflunomide regulatory update

FDA approved an NDA from Sanofi for once-daily oral Aubagio teriflunomide to treat relapsing forms of multiple sclerosis (MS). Sanofi plans to launch Aubagio in "a few weeks." The dihydroorotate dehydrogenase (DHODH) inhibitor, which is also under review in Europe, is the second oral MS drug approved in the U.S. The first, ...

Read the full 251 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >